KEI Staff's blog

Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes

Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.

US ITC notice for public comment, Jan 13, 2016 hearing, and Commission report on the TransPacific Partnership Agreement (TPP)

Here is the US International Trade Commission (USITC) notice for the public hearing, public comments and Commission report on the Trans-Pacific Partnership Agreement (TPP). The deadlines and other requirements for participation may be strictly enforced. Note the ITC anticipates transmitting its report to the President and the Congress on May 18, 2016.

http://www.usitc.gov/secretary/fed_reg_notices/332/tpa_105_001_notice11172015sgl.pdf

Letter from six NGOs to Obama on the WTO LDC patent waiver negotiation

Six NGOs — including Oxfam America, Health GAP, Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT), the Young Professionals Chronic Disease Network (YP-CDN), and Public Citizen — sent a letter to President Obama today asking him to publicly express the United States’ “full and unconditional support” for the waiver of World Trade Organization (WTO) drug patent rules for Least Developed Countries (LDCs).

Final draft, India National IPR Policy, by IP Think Tank constituted by DIPP, Ministry of Commerce and Industry

This is a copy of recommendations for an Indian National IPR Policy, written by the "IP Think Tank," which was constituted by the Department of Industrial Policy & Promotion(DIPP), Ministry of Commerce and Industry, Government of India. A copy scanned from a hard copy is here.

The members of the IPR Think Tank were:

  • Justice Prabha Sridevan (Retd) - Chairperson
  • Mrs. Prathiba M. Singh, Senior Advocate - Member
  • Mr. Narendra K. Sabharwal - Member & Convener

Senator Bernie Sanders proposal to expand Veterans access to patented medical inventions

This is a video by Zack Struver about Senator Bernie Sander's proposal to expand Veterans access to patented medical inventions. The video discusses both the proposal by Senator Sanders to give the U.S. Department of Veterans Affairs the authority to use compulsory licenses on patents on medical inventions, including drugs, and the history of "government use" provisions in current U.S. statutes, including 28 U.S.C. 1498, which Sanders proposes modifying.

IMS Health May 2015 comments on patient access to oncology drugs

IMS Health, the global information and technology services company, known for its statistics on sales of drugs, published a study in May 2015 that estimated the global market for oncology drugs now exceeds $100 billion per year.

KEI briefing note on the evolution of TPP negotiating text on patentable subject matter

The attached PDF file is a KEI briefing note on the evolution of certain sections of the TPP negotiating text on patents and patentable subject matter.

Eleven of the 28 House democrats supporting Fast Track write USTR about Medicine IPR issues

Attached is a letter from eleven of the 28 House Democrats that supported the Trade Promotion Authority (TPA) Fast Track legislation, on the topic of intellectual property rights and medicine. The letter, which is moderate and cautious in substance, but overall helpful given where negotiations stand, closes by telling Ambassador Froman that "As members who support trade done right, we strongly believe that TPP must not inhibit access to lifesaving medicines."

Seminars on Drug Pricing: Part 2, Ruth Lopert

Ruth LopertOn Thursday, 23 July 2015, at 11AM Eastern Time (Washington, DC), KEI will host a seminar on drug pricing featuring Dr. Ruth Lopert, the Deputy Director of Pharmaceutical Policy and Strategy at the Center for Pharmaceutical Management, at Management Sciences for Health (MSH).

Duke letter to White House on the problems with the TPP IP Chapter

Attached below is a May 20, 2015 letter from Duke researchers to the White House Office of Science and Technology Policy, setting our problems in the TPP IP Chapter. The letter is signed by Jason Cross, the Director of the Innovation & Technology Policy Lab (ITPLab) at the Sanford School of Public Policy & Duke Law School, at Duke University.

The whole letter (available in PDF format here) is worth reading. Here are a few sections from the letter:


KEI TPP Briefing note 2015:1 Compulsory licenses on patents and the 3-step test

This is a briefing note prepared for TPP negotiators, addressing a single but important issue, the standards for issuing compulsory licenses in the TPP.

Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.

Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary "to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease."

KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)

Andy-IMG_3181_600x.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.

KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data

Rajasingh-1-IMG_3157_1024x716.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:

NIH refuses to give information about principals in company seeking exclusive license to HCV patents

The NIH provided these responses to four questions about the HCV drug patent license it is considering.

Syndicate content